| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1994PNAS...91.1701Y |
| P356 | DOI | 10.1073/PNAS.91.5.1701 |
| P932 | PMC publication ID | 43231 |
| P698 | PubMed publication ID | 8127868 |
| P5875 | ResearchGate publication ID | 15071121 |
| P50 | author | Andrew Schally | Q141147 |
| P2093 | author name string | T Yano | |
| J Pinski | |||
| S Radulovic | |||
| P2860 | cites work | Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture | Q24631017 |
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata | Q28342702 | ||
| LIGAND: A versatile computerized approach for characterization of ligand-binding systems | Q29547346 | ||
| Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone | Q33841289 | ||
| Receptor-mediated internalization of fluorescent gonadotropin-releasing hormone by pituitary gonadotropes | Q36415911 | ||
| Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells | Q36895986 | ||
| Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. | Q36895998 | ||
| Endocrine Factors in Common Epithelial Ovarian Cancer* | Q37176622 | ||
| Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium | Q41685614 | ||
| Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins | Q42471223 | ||
| Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors | Q42509019 | ||
| A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers | Q42812357 | ||
| Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. | Q42822730 | ||
| New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. | Q43756005 | ||
| Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes | Q44032844 | ||
| Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. | Q44603662 | ||
| Cancer statistics, 1992 | Q53850140 | ||
| Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. | Q54342471 | ||
| Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists* | Q58854013 | ||
| Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells | Q63359359 | ||
| Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH | Q67288472 | ||
| Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model | Q67517790 | ||
| Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH | Q67550875 | ||
| Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines | Q68234196 | ||
| Localization of gonadotropin binding sites in human ovarian neoplasms | Q69357943 | ||
| Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata | Q69492544 | ||
| Advanced ovarian carcinoma: response to the agonist D-Trp-6-LHRH | Q69988394 | ||
| 22 Receptor-mediated endocytosis of epidermal growth factor | Q70193026 | ||
| Some observations on the effect of a GnRH analog in ovarian cancer | Q93519708 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| cell growth | Q189159 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1701-1705 | |
| P577 | publication date | 1994-03-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone | |
| P478 | volume | 91 |
| Q73535650 | Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth |
| Q74415078 | Comparison of animal models for the evaluation of radiolabeled androgens |
| Q54787676 | Cytoplasmic versus nuclear localization of Fos-related proteins in the frog, Rana esculenta, testis: in vivo and direct in vitro effect of a gonadotropin-releasing hormone agonist. |
| Q47703260 | Effects of LHRH-analogues on mitogenic signal transduction in cancer cells |
| Q56386900 | Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues |
| Q37264501 | Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1 |
| Q40946695 | Frontiers of Ovarian Cancer Therapy |
| Q37311391 | Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. |
| Q37311388 | Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. |
| Q33541940 | Hormonal interactions in ovarian cancer |
| Q40818178 | In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses. |
| Q35614963 | Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. |
| Q34204370 | LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action |
| Q71611166 | Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group |
| Q28207118 | Multi-factorial role of GnRH-I and GnRH-II in the human ovary |
| Q44587948 | Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. |
| Q21245571 | Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer |
| Q30983330 | Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. |
| Q28238916 | The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans |
| Q37796219 | The role of peripheral gonadotropin-releasing hormone receptors in female reproduction |
| Q34772221 | Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. |
Search more.